Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-guided peginterferon alfa-2b plus ribavirin in people with chronic hepatitis C genotype 2 or 3 and ongoing injection drug use
2010-024557-36Phase 4Completed
- Sponsor
- The Kirby Institute
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peginterferon alfa-2b and ribavirin in hepatitis C virus infection, sponsored by The Kirby Institute. Primary endpoints: SVR12 and RVR. Started Feb 2012; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-024557-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024557-36.